Reduced Bax levels are commonly observed in enhanced resistance towards chemotherapy in various cancers including chronic lymphocytic leukemia, prostate, liver, colorectal, and lung cancers (29, 30). This evidence concerns the gene BAX and B-cell chronic lymphocytic leukemia.